HomeCompareSPHRF vs PLD

SPHRF vs PLD: Dividend Comparison 2026

SPHRF yields 606.06% · PLD yields 3.10%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SPHRF wins by $280365.26M in total portfolio value
10 years
SPHRF
SPHRF
● Live price
606.06%
Share price
$0.33
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$280371.17M
Annual income
$211,667,981,687.60
Full SPHRF calculator →
PLD
PLD
● Live price
3.10%
Share price
$132.18
Annual div
$4.10
5Y div CAGR
74.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$5.91M
Annual income
$4,750,725.19
Full PLD calculator →

Portfolio growth — SPHRF vs PLD

📍 SPHRF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSPHRFPLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SPHRF + PLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SPHRF pays
PLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SPHRF
Annual income on $10K today (after 15% tax)
$51,515.15/yr
After 10yr DRIP, annual income (after tax)
$179,917,784,434.46/yr
PLD
Annual income on $10K today (after 15% tax)
$263.66/yr
After 10yr DRIP, annual income (after tax)
$4,038,116.41/yr
At 15% tax rate, SPHRF beats the other by $179,913,746,318.05/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SPHRF + PLD for your $10,000?

SPHRF: 50%PLD: 50%
100% PLD50/50100% SPHRF
Portfolio after 10yr
$140188.54M
Annual income
$105,836,366,206.39/yr
Blended yield
75.50%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PLD right now

SPHRF
No analyst data
Altman Z
11.2
Piotroski
3/9
PLD
Analyst Ratings
25
Buy
16
Hold
1
Sell
Consensus: Buy
Price Target
$136.00
+2.9% upside vs current
Range: $119.00 — $155.00
Altman Z
1.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SPHRF buys
0
PLD buys
0
No recent congressional trades found for SPHRF or PLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSPHRFPLD
Forward yield606.06%3.10%
Annual dividend / share$2.00$4.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%74.4%
Portfolio after 10y$280371.17M$5.91M
Annual income after 10y$211,667,981,687.60$4,750,725.19
Total dividends collected$274648.71M$5.78M
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: SPHRF vs PLD ($10,000, DRIP)

YearSPHRF PortfolioSPHRF Income/yrPLD PortfolioPLD Income/yrGap
1← crossover$71,306$60,606.06$11,241$540.96+$60.1KSPHRF
2$480,183$403,885.93$13,019$991.13+$467.2KSPHRF
3$3,055,680$2,541,883.57$15,801$1,870.97+$3.04MSPHRF
4$18,386,820$15,117,242.14$20,609$3,701.21+$18.37MSPHRF
5$104,687,331$85,013,433.96$29,919$7,867.97+$104.66MSPHRF
6$564,382,839$452,367,394.46$50,631$18,617.74+$564.33MSPHRF
7$2,883,114,581$2,279,224,943.60$105,528$51,352.20+$2883.01MSPHRF
8$13,966,501,456$10,881,568,854.67$287,364$174,449.42+$13966.21MSPHRF
9$64,208,586,900$49,264,430,341.75$1,081,760$774,280.77+$64207.51MSPHRF
10$280,371,169,670$211,667,981,687.60$5,908,209$4,750,725.19+$280365.26MSPHRF

SPHRF vs PLD: Complete Analysis 2026

SPHRFStock

Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. It offers VivaGel, a non-antibiotic therapy for the treatment and prevention of bacterial vaginosis. The company also develops VivaGel condom, an antiviral condom; and VIRALEZE, an antiviral nasal spray. In addition, it develops DEP, a dendrimer drug delivery technology, including DEP docetaxel that is in Phase 2 clinical trials, DEP cabazitaxel that is in Phase 2 clinical trial, DEP gemcitabine that is in a Phase 1/2 clinical trials, and DEP irinotecan that is in Phase 2 clinical trials for the treatment of cancer; DEP radiotheranostics for cancer treatment and diagnosis; DEP Antibody Drug Conjugates; DEP HER-2 ADC; DEP non-oncology candidates; and DEP AZD0466, which is in Phase 1/2 clinical trials to treat haematological malignancies. The company was founded in 1996 and is headquartered in Abbotsford, Australia.

Full SPHRF Calculator →

PLDREIT

Prologis, Inc. is the global leader in logistics real estate with a focus on high-barrier, high-growth markets. As of December 31, 2020, the company owned or had investments in, on a wholly owned basis or through co-investment ventures, properties and development projects expected to total approximately 984 million square feet (91 million square meters) in 19 countries. Prologis leases modern logistics facilities to a diverse base of approximately 5,500 customers principally across two major categories: business-to-business and retail/online fulfillment.

Full PLD Calculator →
📬

Get this SPHRF vs PLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SPHRF vs SCHDSPHRF vs JEPISPHRF vs OSPHRF vs KOSPHRF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.